189821-53-2

Usage

Molecular structure

A complex organic compound with a propanone molecule attached to a complex phenolic compound.

Functional groups

Contains a hydroxy group, a methoxy group, a propenyl group, and a hydroxyphenyl group.

Molecular weight

286.32 g/mol

Physical state

Likely a solid or a viscous liquid, depending on temperature.

Solubility

May be soluble in organic solvents like ethanol or acetone, but insoluble in water.

Reactivity

The presence of multiple functional groups may make 1-Propanone, 3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxy phenyl)- reactive in various chemical reactions.

Industrial or medicinal applications

Unknown, but may depend on the properties and reactivity of the compound.

Upstream product

• 87080-27-1 licochalcone A 

Relevant academic research and scientific papers

Modifications of the α,β-double bond in chalcones only marginally affect the antiprotozoal activities

Methods for selective alkylation of chalcones in the α- or β-position and for selective reduction of the α,β-double bond have been developed. The antiparasitic potencies of the α,β-double bond modified chalcones only differ marginally from the potencies of the parent chalcones indicating that the propenone residue only functions as a spacer between the two benzene rings, which are the true pharmacophore. Copyright (C) 1998 Elsevier Science Ltd.

Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones

The invention relates to the use of 1,3-bis-aromatic-prop-2-en-1-ones (chalcones), 1,3-bis-aromatic-propan-1-ones (dihydrochalcones), and 1,3-bis-aromatic-prop-2-yn-1-ones for the preparation of pharmaceutical compositions for the treatment or prophylaxis of a number of serious diseases including i) conditions relating to harmful effects of inflammatory cytokines, ii) conditions involving infection by Helicobacter species, iii) conditions involving infection by viruses, iv) neoplastic disorders, and v) conditions caused by microorganisms or parasites. The invention also relates to novel chalcones and dihydrochalcones (especially alkoxy substituted variants) having advantageous substitution patterns with respect to their effect as drug substances, and to methods of preparing them, as well as to pharmaceutical compositions comprising the novel chalcones. Moreover, the present invention relates to a method for the isolation of Leishmania fumarate reductase, QSAR methodologies for selecting potent compounds for the above-mentioned purposes.